These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 34827413)

  • 41. Paraneoplastic Cerebellar Degeneration in Nasopharyngeal Carcinoma: a Unique Association.
    Bhardwaj S; Khasani S; Benasher D; Stein EG; Meghal T; Jacoby N; Huang YJ
    Cerebellum; 2019 Dec; 18(6):1126-1129. PubMed ID: 31161534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer.
    Sabater L; Bataller L; Carpentier AF; Aguirre-Cruz ML; Saiz A; Benyahia B; Dalmau J; Graus F
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1359-62. PubMed ID: 16801349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice.
    Tanaka K; Tanaka M; Igarashi S; Onodera O; Miyatake T; Tsuji S
    Clin Neurol Neurosurg; 1995 Feb; 97(1):101-5. PubMed ID: 7788964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma.
    Tanriverdi O; Meydan N; Barutca S; Ozsan N; Gurel D; Veral A
    Jpn J Clin Oncol; 2013 May; 43(5):563-8. PubMed ID: 23475537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience.
    Ducray F; Demarquay G; Graus F; Decullier E; Antoine JC; Giometto B; Psimaras D; Delattre JY; Carpentier AF; Honnorat J
    Eur J Neurol; 2014 May; 21(5):731-5. PubMed ID: 24471811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.
    Grativvol RS; Cavalcante WCP; Castro LHM; Nitrini R; Simabukuro MM
    Curr Oncol Rep; 2018 Nov; 20(11):92. PubMed ID: 30415318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antinuclear antibodies (ANA) patterns in paraneoplastic cerebellar degeneration during the course of disease and treatment protocols - A case report.
    Ćerimagić A; Džananović N
    J Transl Autoimmun; 2020; 3():100034. PubMed ID: 32743519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paraneoplastic cerebellar degeneration. Case report and literature review.
    Bolla L; Palmer RM
    Arch Intern Med; 1997 Jun; 157(11):1258-62. PubMed ID: 9183238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.
    Sun X; Tan J; Sun H; Liu Y; Guan W; Jia J; Wang Z
    J Clin Neurol; 2020 Oct; 16(4):530-546. PubMed ID: 33029958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Update on neurological paraneoplastic syndromes.
    Höftberger R; Rosenfeld MR; Dalmau J
    Curr Opin Oncol; 2015 Nov; 27(6):489-95. PubMed ID: 26335665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immune-Mediated Cerebellar Ataxias].
    Mitoma H
    Brain Nerve; 2021 May; 73(5):611-619. PubMed ID: 34006695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Response to abdominal hysterectomy with bilateral salpingo-oophorectomy in postmenopausal woman with anti-yo antibody mediated paraneoplastic cerebellar degeneration.
    Bhargava A; Bhushan B; Kasundra GM; Shubhakaran K; Pujar GS; Banakar B
    Ann Indian Acad Neurol; 2014 Jul; 17(3):355-7. PubMed ID: 25221413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.
    Peter E; Treilleux I; Wucher V; Jougla E; Vogrig A; Pissaloux D; Paindavoine S; Berthet J; Picard G; Rogemond V; Villard M; Vincent C; Tonon L; Viari A; Honnorat J; Dubois B; Desestret V
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35821104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paraneoplastic cerebellar degeneration associated with ovarian cancer.
    Russo AE; Scalone S; Leonardi GC; Scalisi A; Giorda G; Sorio R
    Oncol Lett; 2013 Feb; 5(2):681-683. PubMed ID: 23420048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nodular Sclerosing Hodgkin Lymphoma With Paraneoplastic Cerebellar Degeneration.
    Teh LD; Culp LH; Venable A
    Fed Pract; 2022 Aug; 39(Suppl 3):S18-S19. PubMed ID: 36426105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immune-Mediated Cerebellar Ataxias].
    Mitoma H
    Brain Nerve; 2023 Jun; 75(6):737-747. PubMed ID: 37287357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paraneoplastic cerebellar degeneration associated with breast cancer: A case report and review of the literature.
    Yan L; Dong X; Xu H; Huang J; Wang W; Huang L; Wan Q; Gong J
    Mol Clin Oncol; 2018 Aug; 9(2):163-167. PubMed ID: 30101014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paraneoplastic Cerebellar Degeneration Leading to an Early Diagnosis of Peritoneal Serous Papillary Carcinoma.
    Yasuda T; Shimizu J; Miyagawa T; Tsutsumi Y; Iwatsubo T; Tsuji S
    Intern Med; 2024 Mar; ():. PubMed ID: 38432969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-Ma-associated paraneoplastic cerebellar degeneration in a patient with nodular lymphocyte-predominant Hodgkin lymphoma: a case report.
    Inui R; Saito K; Shimomura Y; Yamashita D; Kawamoto M; Ishikawa T
    BMC Neurol; 2020 Sep; 20(1):355. PubMed ID: 32967629
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Paraneoplasic cerebellar degeneration as a presentation of breast cancer recurrence].
    Gázquez Sisteré I; Caro Orozco S; Márquez Medina D; Chordá Ribelles J; Quílez Martínez A
    An Med Interna; 2007 Mar; 24(3):132-4. PubMed ID: 17590135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.